2. Search Result
Search Result
Results for "

Kunming mice

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

5

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0668
    Rubusoside
    2 Publications Verification

    		 GLUT Amylases NF-κB Metabolic Disease Inflammation/Immunology Cancer
    Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .
    Rubusoside
  • HY-154918
    LysoPE(18:2/0:0)

    		Drug Metabolite Metabolic Disease
    LysoPE (18:2/0:0) is a lysophosphatidylethanolamine implicated in phospholipid metabolism. LysoPE (18:2/0:0) shows significantly altered serum levels in mice exposed to a combination of DEHP (HY-B1945) and Aroclor 1254, which is associated with disturbed phospholipid metabolism. LysoPE (18:2/0:0) can be used for the research of endocrine-disrupting compound-induced metabolic disorders and lipid metabolism disturbance. LysoPE (18:2/0:0) is identified as a potential biomarker for the combined toxicity of DEHP and Aroclor 1254 .
    LysoPE(18:2/0:0)
  • HY-W088065
    Sodium formate

    		Environmental Pollutants DNA/RNA Synthesis Others
    Sodium formate acts as a key promoter for heterogeneous nucleation of ZIF crystals and thin film synthesis. It is also recognized as a GRAS substance by the FDA, and serves as a cosmetic preservative and food additive. Sodium formate has low acute oral toxicity (acute oral LD50=7410 mg/kg and acute intravenous LD50=807 mg/kg in mice), with no heritable or carcinogenic effects, but exhibits embryonic developmental toxicity and teratogenicity at high concentrations. Sodium formate may cause moderate irritation to rabbit eyes, is relatively safe to the skin, and does not induce tumor formation in rats in vivo. Sodium formate is rapidly absorbed and oxidized to carbon dioxide in vivo, and forms DNA adducts in specific metabolic deficiency models or upon high-dose exposure .
    Sodium formate
  • HY-W014901
    Bisphenol F

    BPF; 4,4'-Dihydroxydiphenylmethane

    		 Reactive Oxygen Species (ROS) Akt GSK-3 Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Endocrinology
    Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .
    Bisphenol F
  • HY-N0430
    Coptisine

    Coptisin

    		 Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Coptisine is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine is a reversible, uncompetitive IDO inhibitor with a Ki of 5.8 μM and an IC50 of 6.3 μM. Coptisine suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine can be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .
    Coptisine
  • HY-146754
    MMP2-IN-1
    1 Publications Verification

    		 MMP Apoptosis Cancer
    MMP2-IN-1 is a moderate potenet MMP2 inhibitor with IC50 of 6.8 µM. MMP2-IN-1 exhibits remarkable antiproliferative activity in certain cancer cells by arresting the cell cycle and inducing apoptosis .
    MMP2-IN-1
  • HY-N11546
    Sapindoside B

    		Cytochrome P450 Bacterial Fungal Infection Cancer
    Sapindoside B is a substance with hepatoprotective activity, and also acts as a cytochrome P-450 (cytochrome P-450) inhibitor, antibacterial agent and membrane-disrupting agent. Sapindoside B reversibly inhibits the content of cytochrome P-450 in liver microsomes, suppresses the phenobarbital-induced increase in enzyme content, reduces the production of active metabolites mediated by cytochrome P-450, and alleviates hepatotoxic injury. Sapindoside B binds to Cutibacterium acnes lipase, reduces lipase activity, inhibits biofilm formation, and decreases bacterial adhesion. Sapindoside B exhibits cytotoxicity against human cancer, liver cancer, leukemia and glioblastoma cells. Sapindoside B inhibits mycelial growth of phytopathogenic fungal strains, possesses antibacterial activity against dermatophytes, and also has hemolytic/membrane-lytic activity. Sapindoside B can be used in research related to liver injury, Cutibacterium acnes biofilm-associated infections, gastric cancer, carcinoma, promyelocytic leukemia, glioblastoma, apple scab and grape gray mold .
    Sapindoside B
  • HY-N0668R
    Rubusoside (Standard)

    		GLUT Amylases NF-κB Reference Standards Metabolic Disease Inflammation/Immunology Cancer
    Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase) .
    Rubusoside (Standard)
  • HY-W026339
    IMB-XMA0038

    		Bacterial Infection
    IMB-XMA0038 is a MtASADH inhibitor with an IC50 value of 0.59 μg/mL. IMB-XMA0038 inhibits various agent-resistant Mycobacteria tuberculosis potently with MICs of 0.25-0.5 μg/mL. IMB-XMA0038 shows anti-tuberculosis activity .
    IMB-XMA0038
  • HY-151967
    Anti-IAV agent 1

    		Influenza Virus Infection
    Anti-IAV agent 1 (Compound (R)-1a) is an orally active anti-influenza A virus (IAV) agent with IC50s of 0.03 and 0.06 μM against IAV H1N1 and Oseltamivir-resistant IAV H1N1 strains, respectively .
    Anti-IAV agent 1
  • HY-173216
    Pseudorabies virus-IN-1

    		DNA/RNA Synthesis HSV Infection
    Pseudorabies virus-IN-1 is a potent pseudorabies virus (PRV) inhibitor (EC50: 0.29 nM). Pseudorabies virus-IN-1 inhibits PRV replication by targeting PRV deoxyribonucleic acid polymerase (DNA pol). Pseudorabies virus-IN-1 can effectively inhibit PRV replication at low concentrations (MIC80: 1.6-8 nM). Pseudorabies virus-IN-1 can be used to study PRV infection .
    Pseudorabies virus-IN-1
  • HY-150545
    AChE-IN-21

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-21 (Compound I-8) is a potent, selective and orally active AChE inhibitor with an IC50 of 2.66 nM. AChE-IN-21 displays excellent BBB permeability in vitro .
    AChE-IN-21
  • HY-183658
    URAT1/GLUT9-IN-3

    		URAT1 GLUT Metabolic Disease Inflammation/Immunology
    URAT1/GLUT9-IN-3 is an orally active URAT1/GLUT9 dual inhibitor with IC50 values of 4.01 and 1.60 μM. URAT1/GLUT9-IN-3 inhibits URAT1-mediated uric acid uptake and GLUT9-mediated uric acid transport, reducing renal urate reabsorption. URAT1/GLUT9-IN-3 reduces serum uric acid levels in hyperuricemic mice. URAT1/GLUT9-IN-3 can be used for the researches of gout and hyperuricemia .
    URAT1/GLUT9-IN-3
  • HY-183341
    sEH/AChE-IN-5

    		Cholinesterase (ChE) Epoxide Hydrolase TNF Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    sEH/AChE-IN-5 is a selective, orally active and brain-penetrant acetylcholinesterase (AChE) and soluble epoxide hydrolase (sEH) dual inhibitor with IC50 values of 1.7 nM and 0.7 nM. sEH/AChE-IN-5 mediates neuroprotection and anti-inflammation via reduced TNF-α, IL-1β, IL-6, iNOS. sEH/AChE-IN-5 improves Scopolamine (HY-N0296)-induced learning and memory deficits mice. sEH/AChE-IN-5 can be used for the research of Alzheimer's disease .
    sEH/AChE-IN-5
  • HY-181520
    ABCA1 inducer 3

    		ATP-binding cassette (ABC) transporters Metabolic Disease
    ABCA1 inducer 3 (Compound 85) is an orally active ABCA1 inducer and lipid-modulating agent. ABCA1 inducer 3 increases ABCA1 expression. ABCA1 inducer 3 upregulates hepatic Abcg5 and Abcg8 mRNA expression. ABCA1 inducer 3 promotes cholesterol efflux. ABCA1 inducer 3 improves hyperlipidemia .
    ABCA1 inducer 3
  • HY-P11655
    NOTA-TATE

    		Somatostatin Receptor Neurological Disease
    NOTA-TATE is a somatostatin receptor 2 (SSTR2) binder. NOTA-TATE binds to SSTR2 to enable targeting of SSTR2-positive tumour cells for PET imaging. NOTA-TATE can be used for the research of neuroendocrine tumours .
    NOTA-TATE
  • HY-171699
    Antibacterial agent 339

    		Bacterial Infection
    Antibacterial agent 339 is an antibacterial agent. Antibacterial agent 339 inhibits the growth of Fusarium oxysporum f.sp.cubense Race 4 with a MIC of 50.5 μM. Antibacterial agent 339 shows low toxicity in mice. FLT3-IN-30 can be used for the research of banana wilt .
    Antibacterial agent 339
  • HY-P1654A
    A20FMDV2-Cys

    		Integrin Cancer
    A20FMDV2-Cys is a cysteine-containing 20-mer peptide that targets integrin αvβ6 with high affinity. A20FMDV2-Cys can be used for targeted liposome modification to enhance liver and bile duct targeting. A20FMDV2-Cys is applicable for research in drug delivery .
    A20FMDV2-Cys
  • HY-183355
    KRAS G12D-IN-37

    		Ras ERK Akt Reactive Oxygen Species (ROS) Apoptosis Bcl-2 Family Caspase Cancer
    KRAS G12D-IN-37 is a KRAS G12D inhibitor. KRAS G12D-IN-37 shows antiproliferative activity against KRAS G12D mutant tumor cells and minimal cytotoxicity toward normal cells. KRAS G12D-IN-37 binds stably to KRAS G12D via hydrogen bond interactions with residues His 95, Arg 68, and Asp 12, and inhibits downstream ERK/AKT signaling pathways. KRAS G12D-IN-37 elevates ROS levels, induces apoptosis, disrupts mitochondrial membrane potential. KRAS G12D-IN-37 downregulates the level of anti-apoptotic protein Bcl-2, and upregulates the levels of pro-apoptotic proteins Bax and caspase 3. KRAS G12D-IN-37 can be used for the research of cancer, such as gastric adenocarcinoma and colorectal cancer .
    KRAS G12D-IN-37
  • HY-181080
    TOP1/TDP1-IN-1

    		Topoisomerase DNA/RNA Synthesis Apoptosis Cancer
    TOP1/TDP1-IN-1 is a DNA topoisomerase 1B (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor with a TDP1 IC50 of 17.8 μM. TOP1/TDP1-IN-1directly suppresses TOP1 catalytic activity without forming a DNA-TOP1 ternary complex, inhibits TDP1-mediated repair of TOP1-induced DNA damage, and exhibits low acute toxicity. TOP1/TDP1-IN-1 disrupts DNA repair pathways, induces apoptosis, suppresses clonogenic growth, and elicits antiproliferative effects in cancer cells. TOP1/TDP1-IN-1 can be used for the research of non-small cell lung cancer, cervical cancer, colon cancer .
    TOP1/TDP1-IN-1
  • HY-182679
    L0909

    		HCV Infection
    L0909 is an HCV inhibitor with an EC50 of 0.022 μM. L0909 blocks HCV replication by inhibiting E1-mediated viral entry. L0909 exhibits sensitivity to clinical resistant HCV mutants. L0909 displays synergistic effects with clinical HCV drugs. L0909 can be used for the research of hepatitis c virus (HCV) infection .
    L0909

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: